4Kleijnen J, Chalmers Ⅰ. How to practice and teach evidence-based medicine: role of the cochrane collaboration. Acta Anaesthesiol Scand Suppl, 1997,111 :231-233.
2Jeffrey RG, Mitchell SS. Gene therapy in urologic oncology. World J Urol, 2000 , 18:91 - 92.
3Eastham JA, Grafton W; Martin CM, et al. Suppression of primary tumor growth and the progression to metastasis with p53 adenovirus in human prostate cancer. J Urol, 2000 , 164:814-819.
4Lin SH, Pu YS, Luo W, et al. Schedule - dependence of CCAM1 adenovirus gene therapy in a prostate cancer model. Anticancer Res, 1999,19:337 - 340.
5Cairns P, Polascik TJ, Eby Y, et al. Frequency of Homozygous deletion at p16/CDKN2 in primary human tumors. Nat Genet,1995,11:90 - 94.
6Allay JA, Steiner MS, Zhang Y, et al. Adenovirus p16 gene therapy for prostate cancer. World J Urol, 2000,18:111 - 120.
7Dorai T, Olsson CA, Katz AE, et al. Development of a hammerhead ribozyme against bel - 2. I. Preliminary evaluation of a potential gene therapeutic agent for horomone - refractory human prostate cancer. 1997, 32:246- 258.
8Dorai T, Perlman H,Walsh K, et al. Enhanced apoptosis of prostate cancer cells by adenoviral hammerhead ribozyme mediated disruption of bel - 2. Presented at annual meeting of American Association for Cancer Research, Philadelphia, April 10- 14, 1999.
9Segawa T,Takebayashi H, Kakehi Y, et al. Prostate- specific amplification of expanded polyglutamine expression: a novel approach for cancer gene therapy. Cancer Res 1998,58:2282 - 2287.
10Hyer ML, Rubinchik S, Dong JY, et al. Gene therapy of prostatae cancer with adenovirus- mediated fas ligang (FasL) expression. Presented at annual meeting of American Association for Cancer Research, Philadelphia, April 10- 14, 1999.
5Mansfield JT, Stephenson RA. Dose transurethral resection of the prostale compromise the radical Ⅱ reatmenl of the prostale cancer [ J ]. Semin Urol Oncol, 1996 (3) :71 - 72.
